• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evaluation of structural modification induced activation of pneumococcal polysaccharide by GC-MS for the conjugate vaccine
Carbohydr Res. 2023 Jun 25;531:108878. doi: 10.1016/j.carres.2023.108878. Online ahead of print.ABSTRACTPolysaccharide (Ps) activation evaluation is an imperative quality attribute in a conjugate vaccine. Pneumococcal polysaccharide (PnPs) serotypes 5, 6B, 14, 19A and 23F were cyanylated for 3 and 8 min. The cyanylated and non-cyanylated polysaccharides were methanolysed and derivatized to assess the activation of each sugar by GC-MS. The activation of 22 and 27% serotype 6B and 11 and 36% in serotype 23 F Ps at 3 and 8 min respectively showed controlled conjugation kinetics with CRM197 carrier protein estimated by SEC-HPL...
Source: Carbohydrate Research - June 30, 2023 Category: Genetics & Stem Cells Authors: Niraj Shende Abhijeet Karale Prashant Bore Sudhakar Bhagade Ashishkumar Gulhane Asha D Mallya Rajeev M Dhere Source Type: research

Identification of a Novel Keto Sugar Component in Streptococcus pneumoniae Serotype 12F Capsular Polysaccharide and Impact on Vaccine Immunogenicity
J Immunol. 2023 Feb 1:ji2100849. doi: 10.4049/jimmunol.2100849. Online ahead of print.ABSTRACTImplementation of conjugate vaccine technology revolutionized the ability to effectively elicit long-lasting immune responses to bacterial capsular polysaccharides. Although expansion of conjugate vaccine serotype coverage is designed to target residual disease burden to pneumococcal serotypes not contained in earlier vaccine versions, details of polysaccharide Ag structure, heterogeneity, and epitope structure components contributing to vaccine-mediated immunity are not always clear. Analysis of Streptococcus pneumoniae serotype ...
Source: Journal of Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Kelly Sackett Paul Brown Kaushik Dutta Ingrid L Scully Seema Gangolli Kelvin Looi Sandeep Nemani Angela Yeou Hsiung Yu Mark Kleven Jin Xie Justin Moran Michael W Pride Annaliesa S Anderson Jason Lotvin Source Type: research

JMM Profile: < em > Streptococcus pneumoniae: < /em > sugar-coated captain of the men of death
J Med Microbiol. 2021 Nov;70(11). doi: 10.1099/jmm.0.001446.ABSTRACTStreptococcus pneumoniae is a highly adept human pathogen. A frequent asymptomatic member of the respiratory microbiota, the pneumococcus has a remarkable capacity to cause mucosal (pneumonia and otitis media) and invasive diseases (bacteremia, meningitis). In addition, the organism utilizes a vast battery of virulence factors for tissue and immune evasion. Though recognized as a significant cause of pneumonia for over a century, efforts to develop more effective vaccines remain ongoing. The pathogen's inherent capacity to exchange genetic material is crit...
Source: Journal of Medical Microbiology - November 15, 2021 Category: Microbiology Authors: Tina H Dao Jason W Rosch Source Type: research

Bacterial surface capsular polysaccharides from Streptococcus pneumoniae: A systematic review on structures, syntheses, and glycoconjugate vaccines
Carbohydr Res. 2021 Mar 10;502:108277. doi: 10.1016/j.carres.2021.108277. Online ahead of print.ABSTRACTThe polysaccharide capsule of Streptococcus pneumoniae constitutes the outermost surface structure of the organism and plays a critical role in virulence. The capsule is the target of current pneumococcal vaccines and glycoconjugates and has important medical and industrial applications. Widespread use of these vaccines is driving changes in serotype prevalence in disease. A massive array of sugars and glycosidic linkages experienced with complete diversity of potential polysaccharide structures. However, it is impossibl...
Source: Carbohydrate Research - March 20, 2021 Category: Genetics & Stem Cells Authors: None Javed Pintu Kumar Mandal Source Type: research

Pages: 1  2